National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Simeprevir (Olysio®) in combination with Sofosbuvir for the treatment of chronic hepatitis C (CHC) in adult patients who are intolerant to or ineligible for interferon therapy, and are in urgent need of treatment.

Rapid Review

Commenced Completed Outcome
27/05/2014 11/07/2014 Full Pharmacoeconomic Assessment Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
30/10/2014  13/03/2015 Reimbursement recommended in some subgroups

The NCPE recommends reimbursement of simeprevir in combination with sofosbuvir for genotype 1 in some subgroups

Summary